Interval colorectal cancer

1. Sex was not clearly linked with interval colorectal cancer in humans (Complete-case quantitative cohort; adjustment for fecal hemoglobin).

   “The quantitative cohort showed no clear sex difference after adjustment for f-Hb.”

   HumansComplete-case quantitative cohort; adjustment for fecal hemoglobinUp to 24 months

   Blood traces in negative stool tests link to bowel cancer risk

   medRxiv·Oct 28, 2026Preprint

1. Fecal hemoglobin is associated with interval colorectal cancer in humans (Complete-case quantitative cohort; maximum fecal hemoglobin >15–<20 ug/g versus 0–5 ug/g) (Adjusted HR 14.93 (9.02–24.70); 24-month risks 504.5 versus 35.7 per 100,000 episodes).

   “Compared with maximum f-Hb of 0-5 ug/g, concentrations >15-<20 ug/g were associated with an adjusted HR of 14.93 (9.02-24.70).”

   HumansComplete-case quantitative cohort; maximum fecal hemoglobin >15–<20 ug/g versus 0–5 ug/g24 months

   Blood traces in negative stool tests link to bowel cancer risk

   medRxiv·Oct 28, 2026Preprint

More on Fecal hemoglobin

1. Male sex is associated with interval colorectal cancer in humans After negative fecal immunochemical testing; adjusted analysis (Adjusted HR 1.28, 95% CI 1.08–1.50).

   “Risk increased with age and was higher in males (adjusted HR 1.28, 95% CI 1.08-1.50).”

   HumansAfter negative fecal immunochemical testing; adjusted analysisUp to 24 monthsn = 700,734

   Blood traces in negative stool tests link to bowel cancer risk

   medRxiv·Oct 28, 2026Preprint

1. Age is associated with interval colorectal cancer in humans After negative fecal immunochemical testing.

   “Risk increased with age”

   HumansAfter negative fecal immunochemical testingUp to 24 monthsn = 700,734

   Blood traces in negative stool tests link to bowel cancer risk

   medRxiv·Oct 28, 2026Preprint

1. Interval colorectal cancer is associated with mortality in humans (23.0% vs 10.8%, P < 0.001).

   “Interval CRCs were associated with worse 2-year all-cause mortality than screen-detected CRCs (23.0 versus 10.8%; P < 0.001).”

   Humans2 yearsn = 546

   Risk factors and clinical consequences of interval cancers arising within faecal immunochemical testing-based colorectal cancer screening programme

   BJS open·Sep 8, 2025